GlassScriptPhysician profile
Troy J Ehrhart
NPI 1003913021
$2,341.95
in general payments reported to CMS, 2019-2025
26 companies · $18.63 in 2025
The $18.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $213 · 2021: $483 · 2022: $520 · 2023: $228 · 2025: $18.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $514.87 | 2019-2022 | |
| Novo Nordisk INC | $298.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $225.02 | 2019-2023 | Jardiance, Emgality |
| Pfizer INC. | $177.89 | 2019-2023 | |
| Abbvie INC. | $176.72 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $114.41 | 2021-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $95.41 | 2019-2022 | |
| Amgen INC. | $94.73 | 2019-2021 | |
| Boston Scientific Corporation | $76.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.69 | 2019-2021 | |
| Allergan, INC. | $35.57 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $34.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $30.24 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $28.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.54 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.47 | 2019-2020 | |
| Amarin Pharma, INC. | $24.38 | 2021 | |
| Si-Bone, INC. | $22.86 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.53 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.32 | 2022 | |
| Abbott Laboratories | $12.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.29 | 2022 | |
| Ironshore Pharmaceuticals INC. | $10.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Ehrhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.